Atea Pharmaceuticals, Inc. (AVIR)

NASDAQ: AVIR · IEX Real-Time Price · USD
3.690
+0.150 (4.24%)
Jul 16, 2024, 10:54 AM EDT - Market open
4.24%
Market Cap 303.20M
Revenue (ttm) n/a
Net Income (ttm) -163.66M
Shares Out 84.22M
EPS (ttm) -1.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 90,678
Open 3.570
Previous Close 3.540
Day's Range 3.540 - 3.700
52-Week Range 2.765 - 4.600
Beta 0.18
Analysts Sell
Price Target n/a
Earnings Date Aug 6, 2024

About AVIR

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 30, 2020
Employees 74
Stock Exchange NASDAQ
Ticker Symbol AVIR
Full Company Profile

Financial Performance

Financial Statements

News

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference

BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral thera...

6 weeks ago - GlobeNewsWire

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial

7 weeks ago - GlobeNewsWire

Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024

BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral thera...

2 months ago - GlobeNewsWire

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

Enrollment Reached Over 2,200 High-Risk Patients in Bemnifosbuvir Monotherapy Cohort Results from SUNRISE-3 Expected in 2H'24 BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nas...

3 months ago - GlobeNewsWire

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment (SVR4) from Lead-in Cohort in Phase 2 HCV Study

4 months ago - GlobeNewsWire

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral ther...

5 months ago - GlobeNewsWire

Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19

A 98% Sustained Virologic Response at Week 4 (SVR4) Post-Treatment Observed in Initial Data From 52 Patients in Lead-In Cohort in Phase 2 HCV Study

6 months ago - GlobeNewsWire

Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral ther...

6 months ago - GlobeNewsWire

Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

First Clinical Data for Coadministration of Bemnifosbuvir and Ruzasvir Show Combination Was Well Tolerated in a Phase 1 Study

8 months ago - GlobeNewsWire

Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

P atient enrollment continues in global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for COVID-19; first interim analysis expected 1Q24

8 months ago - GlobeNewsWire

Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences

BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral ther...

8 months ago - GlobeNewsWire

Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023

BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral ther...

9 months ago - GlobeNewsWire

Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral the...

11 months ago - GlobeNewsWire

Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral ther...

1 year ago - GlobeNewsWire

Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023

BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral ther...

1 year ago - GlobeNewsWire

Atea Pharmaceuticals' Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners' Affiliate, Concentra Biosciences

Proposal Fundamentally Undervalues Atea; Not in the Best Interests of Atea or Its Shareholders Proposal Fundamentally Undervalues Atea; Not in the Best Interests of Atea or Its Shareholders

1 year ago - GlobeNewsWire

Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners' Affiliate, Concentra Biosciences

BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Bioscien...

1 year ago - GlobeNewsWire

Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

Global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 in high-risk patients continues enrollment; execution of global geographic footprint

1 year ago - GlobeNewsWire

Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023

BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral thera...

1 year ago - GlobeNewsWire

Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19

BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral the...

1 year ago - GlobeNewsWire

Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases

71% reduction in risk of hospitalization for mild to moderate COVID-19 outpatients treated with bemnifosbuvir versus placebo in MORNINGSKY study, regardless of vaccination status 71% reduction in risk...

1 year ago - GlobeNewsWire

New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research

Low risk for drug-drug interactions with bemnifosbuvir based upon results from in vitro metabolism and transporter studies

1 year ago - GlobeNewsWire

New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research

BOSTON, March 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting...

1 year ago - GlobeNewsWire

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 in high-risk patients continues enrollment; interim analysis expected in 2H23

1 year ago - GlobeNewsWire

Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023

Results highlight the favorable profile for bemnifosbuvir related to low risk for drug-drug interactions

1 year ago - GlobeNewsWire